0.7212
Pavmed Inc Borsa (PAVM) Ultime notizie
PAVmed switches to new accounting firm post-acquisition - Investing.com Australia
PAVmed switches to new accounting firm post-acquisition By Investing.com - Investing.com South Africa
PAVmed, Lucid post encouraging results from EsoGuard study (LUCD:NASDAQ) - Seeking Alpha
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD - StreetInsider
Breakthrough: NCI Study Validates EsoGuard's Perfect Accuracy for Early Cancer Detection$60B Market Impact - Stock Titan
PAVmed Files Prospectus Relates To Potential Offer, Sale From Time To Time Of 3.3 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume - ADVFN
PAVmed Provides Business Update and Second Quarter 2024 Financial Results - ADVFN
Lucid Diagnostics finalizes public offering of common stock - Medical Buyer
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock - The Bradford Era
Lucid Diagnostics Closes $16.1 Million Public Offering - MSN
PAVmed (PAVM) Stock Price, News & Analysis - MarketBeat
PAVmed subsidiary completes $16.1M stock offering By Investing.com - Investing.com Canada
PAVmed subsidiary completes $16.1M stock offering - Investing.com Australia
Lucid Diagnostics completes $16.1 million stock offering By Investing.com - Investing.com South Africa
Lucid Diagnostics Raises $16.1 Mln Through Public Offering To Support Corporate Growth - Nasdaq
Lucid Diagnostics Announces Closing of Public Offering of Common Stock - GuruFocus
Lucid Diagnostics completes $16.1 million stock offering - Investing.com Australia
Indo-Asian News Service - Indo-Asian News Service (IANS)
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock (PR Newswire) - Aktiellt
Lucid Diagnostics Announces Proposed Public Offering of Common Stock - The Malaysian Reserve
Lucid Diagnostics announces proposed public offering of common stock - MSN
Medical Diagnostics Pioneer Lucid Secures $15M Strategic Financing Round - Stock Titan
Lucid Diagnostics plans stock offering to boost capital By Investing.com - Investing.com South Africa
Lucid Diagnostics Announces Proposed Public Offering of Common S - GuruFocus
SEC Form 424B5 filed by Lucid Diagnostics Inc. - Quantisnow
Lucid Diagnostics plans stock offering to boost capital - Investing.com Australia
Commercial-Stage Cancer Prevention Company Lucid Diagnostics Unveils Strategic Funding Move - Stock Titan
Indo-Asian News Service-LUCID DIAGNOSTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK - Indo-Asian News Service (IANS)
Indo-Asian News Service-LUCID DIAGNOSTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK - Indo-Asian News Service (IANS)
PAVmed (PAVM) Files to Sell 3.3 Million Shares - GuruFocus
Pavmed Inc Files For Offering Of 3.3 Million Shares Of Common Stock - marketscreener.com
PAVmed stock touches 52-week low at $0.56 amid market challenges By Investing.com - Investing.com South Africa
PAVmed stock touches 52-week low at $0.56 amid market challenges - Investing.com India
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - BioSpace
Lucid Diagnostics to Participate in Fireside Chat at the 24th An - GuruFocus
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
PAVmed outlines strategic milestones for 2025, including Veris implantable device submission - MSN
Pavmed’s Strategic Growth and Financial Challenges - MSN
PAVmed Inc. (NASDAQ:PAVM) Q4 2024 Earnings Call Transcript - Insider Monkey
Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology - PR Newswire
Game-Changing Cancer Detection: EsoCheck Achieves 99% Accuracy Across 30,000 Patient Study - Stock Titan
PAVmed Inc (PAVM) Q4 2024 Earnings Call Highlights: Strategic Growth and Financial Stability - Yahoo
PAVmed Inc (PAVM) Q4 2024 Earnings Call Highlights: Strategic Gr - GuruFocus.com
PAVmed Reports Strong Q4 Results and Strategic Progress - TipRanks
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):